Regeneron and Telix Announce Strategic Radiopharma Collaboration

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Regeneron's PD-1 inhibitor is a global standard of care for lung cancer

  60% confidence

• At Regeneron, we follow the science to determine the best therapeutic approach for each disease, continuously expanding our toolbox of treatment modalities – from monoclonal and bispecific antibodies to cell therapies and beyond. Targeted radiopharmaceuticals represent a rapidly emerging frontier in oncology and an exciting opportunity to bring new treatment options to patients in need.

  60% confidence

• The collaboration with Regeneron reflects a highly complementary set of capabilities and a unique opportunity to explore what true 'next gen' biologics-based radiopharmaceuticals can potentially do for patients. We are well positioned to work toward the shared goal of advancing next generation precision radiopharmaceuticals for patients with hard-to-treat cancers.

  60% confidence

• Telix brings deep expertise in radiopharmaceutical development and infrastructure that complements Regeneron's antibody technologies and oncology portfolio. Regeneron is excited to enter the targeted radiopharmaceuticals space and explore the utility of these agents either as monotherapy or rationally combined with our immunotherapy platform, particularly in areas of high unmet patient need such as lung cancer, where our PD-1 inhibitor is a global standard of care.

  60% confidence

Cited in these Via News reports

• Global Biotech Valuations Rise as $120B Oncology Pipeline Targets 2026-2027 FDA Approvals →